Great buying at these levels, well done. I suspected as much, as the fundamentals of the company only look to be improving. Most volume we have seen in this company for awhile.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%